Nonviral gene transfer to the suprachoroidal space
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
ophthalmology (suprachoroidal gene transfer)
Modality
Gene Therapy
Mechanism
nonviral suprachoroidal gene transfer
Target
—
rNPV Envelope
Low
-$52.5M
costs +25% · peak −25%
Base
-$39.4M
cumulative PoS 2.0%
High
-$26.3M
costs −25% · peak +25%
This is an illustrative ocular gene-delivery envelope, not a single therapeutic. Costs use ocular gene-therapy benchmarks with some nonviral CMC uncertainty; PoS is conservative because payload, indication, durability, and repeat-dose biology are not defined.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #46 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#33) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Nonviral suprachoroidal nanoparticle gene transfer
The direct technology: suprachoroidal injection of nonviral nanoparticles carrying plasmid payloads to achieve ocular expression without subretinal surgery or viral-vector limitations.
Criteria 1: exact delivery route and modality reality; platform anchor, not product comparator.
ABBV-RGX-314 / surabgene lomparvovec - suprachoroidal AAV ocular gene therapy
Current live clinical archetype for suprachoroidal ocular gene therapy, showing that the route has become clinically relevant but via AAV, not nonviral nanoparticles.
Criteria 2 and 4: same route and therapeutic intent, different vector; live adjacent anchor.
Luxturna / voretigene neparvovec
Approved ocular gene-therapy archetype for regulatory path, one-time administration, and commercial ceiling discipline.
Criteria 3 and 4: approved ocular gene-therapy archetype, not same indication or route.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $18.0M | 24 mo | 36.0% | [0] [1] |
| Phase I | $50.0M | 18 mo | 58.0% | [1] [2] |
| Phase II | $115.0M | 30 mo | 25.0% | [1] [2] [3] |
| Phase III | $240.0M | 42 mo | 46.0% | [2] [3] |
| NDA/BLA Review | $18.0M | 12 mo | 85.0% | [3] |
Multiplier handling: Eligible multipliers (ocular_delivery_platform) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$300.0M peak · WACC 14.0%
Peak revenue. The asset is a delivery-route platform, so full product peak is not the right value-capture metric. The $300M illustrative peak is anchored to ocular gene-therapy commercial reality and a potential partnered payload, not to the entire anti-VEGF market.
WACC. Ocular delivery is clinically attractive but nonviral durability and product definition remain unresolved.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$39.4M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$152.7M
P25
-$47.6M
P50 (median)
-$18.9M
P75
-$11.0M
P95
-$6.0M
Prob ≥ 0
1.7%
Comparable launch curves
Revenue trajectories of named comparators
Luxturna / voretigene neparvovec
Launched 2017 · peak $237.5M (estimated)
Evidence register
5 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is nonviral suprachoroidal delivery, not a single product cmo_findings.asset_class_reality | Nonviral gene transfer to the suprachoroidal space regulatory | 2017-01-01 | high |
Primary nonviral suprachoroidal nanoparticle proof of concept stage_profile.preclinical.pos | Suprachoroidal gene transfer with nonviral nanoparticles peer_review | 2020-07-03 | high |
Suprachoroidal delivery field context comparators[0] | Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases peer_review | 2021-02-01 | high |
Live suprachoroidal gene-therapy clinical archetype comparators[1] | AbbVie and REGENXBIO update on ABBV-RGX-314 clinical program company_filing | 2025-01-13 | medium |
Approved ocular gene-therapy regulatory archetype comparators[2] | Luxturna FDA product page regulatory | 2017-12-19 | high |
Thesis
Why this asset earns its rank
This is an enabling ocular delivery technology, not a single therapeutic asset. The JHU technology is nonviral gene transfer to the suprachoroidal space, a route meant to avoid subretinal surgery, viral cargo constraints, and anti-vector immunity while enabling ocular expression from plasmid/nanoparticle payloads. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified partnership_candidate rather than vc_fundable.
Comparator economics need to stay platform-aware. ABBV-RGX-314 shows that suprachoroidal ocular gene therapy has become clinically relevant, but that program is AAV, not nonviral nanoparticle delivery; Luxturnna anchors the ocular gene-therapy regulatory path and modest commercial reality. The engine result is -$52.5M to -$26.3M, with a base rNPV of -$39.4M and cumulative PoS of 2.0%; that is a partnered-payload envelope, not a product peak for the delivery route itself.
Verdict: partnerable delivery science with real route relevance, but not an investable standalone drug until payload and indication are defined. It earns its rank through gene-therapy modality strength and clinical relevance, while the CMO caveat is that delivery platforms capture royalties/milestones, not full product economics.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: the technology is a delivery route/platform without a specified payload, indication, dose, or clinical candidate.
- Durability risk: nonviral ocular expression may be repeatable but may not match AAV durability, changing the value proposition.
- Competitive route risk: current late-stage suprachoroidal gene therapy is AAV-based, so nonviral nanoparticles must show a clear safety, cargo, or repeat-dose advantage.
- Commercial value capture: JHTV economics would likely be a license/royalty on partnered payloads rather than full product ownership.